(Q40363036)

English

A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.

scientific article published on 21 December 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Efstratios Maltezos

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

K Amarantidis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Trichas

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Vasiliadis

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Toromanidou

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

E Chatzaki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

A Karayiannakis

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

A Tsaroucha

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

K Romanidis

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

S Kakolyris

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

21 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

69

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

463-469

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16374040%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1159%2F000090494

21 January 2018

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

https://api.crossref.org/works/10.1159%2F000090494

21 January 2018

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1159%2F000090494

21 January 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1159%2F000090494

21 January 2018

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1159%2F000090494

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40363036&oldid=1570012812"